{"entity":{"id":"nct07471789","kind":"trial","name":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","aka":[],"tldr":"A phase 1/2 trial of CART84 in acute myeloid leukaemia, run by Gyala Therapeutics, now recruiting.","summary":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). is a phase 1/2 interventional study registered as NCT07471789 by Gyala Therapeutics, with 33 participants planned, started 2026-02-04 and due to reach its primary completion in 2029-05-31. Interventions recorded: CART84.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07471789","url":"https://clinicaltrials.gov/study/NCT07471789"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["cart84"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07471789","phase":"1/2","setting":"Phase I/IIa Clinical Trial With Dose Escalation to Evaluate Safety and Efficacy of the Infusion of CART84 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","sponsor":"Gyala Therapeutics","enrolled":33,"outcomes":[]},"route":"/trials/nct07471789/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"cart84","kind":"drug","name":"CART84","route":"/drugs/cart84/"}]}}